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Clinical Perspectives
Selection of reperfusion therapy for individual patients 
with evolving myocardial infarction
Introduction
The overall benefits of reperfusion therapy for acute 
myocardial infarction have been established un­
equivocally. Physicians can now choose among differ­
ent thrombolytic regimens based on streptokinase 
and tissue plasminogen activator, while other regi­
mens are under development (for example reteplase 
and saruplase). In some hospitals, direct angioplasty 
is an alternative.
Key questions in clinical practice are how 
widely should thrombolytic therapy be used, and 
whether different reperfusion strategies should be 
chosen for different types of patients and in different 
clinical circumstances. This is even more of an issue 
when medical resources are limited. Such decisions 
could be based on simple univariate criteria (older vs 
younger patients, anterior vs inferior infarction) or on 
more complex multivariate modelling. Moreover, 
some consideration of the cost/effectiveness, the 
relative safety and the complexity (e.g. primary 
angioplasty) of different therapeutic options need to 
be taken into account.
On 20 and 21 February 1995, a colloquium 
involving several groups of investigators was organ­
ised to review these issues (Appendix). Prior to the 
meeting, several questions were posed to guide the 
discussion and to attempt to obtain consensus:
1. Reperfusion therapy preserves viable myocardial 
tissue and reduces mortality in acute myocardial 
infarction patients. Are left ventricular ejection 
fraction and infarct size adequate 'surrogate9 mea­
sures for the effects on mortality and morbidity?
2. Mortality with or without reperfusion therapy can 
be predicted by individual characteristics. What 
are the short-term effects of reperfusion therapy in 
different subgroups of patients?
3. Improved survival with reperfusion therapy is sus­
tained after the first year. What are the determi­
nants of the long-term survival advantage after 
reperfusion therapy?
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4. The mortality reduction produced by reperfusion 
therapy is related to the time from symptom onset 
to treatment. W hat is the nature of this relation­
ship? Is there a first cgolden hour’ after symptom 
onset in which treatment benefits are particularly 
large?
5. Do patients treated late after onset of symptoms — 
between 12 and 24 h —  also benefit from reper­
fusion therapy?
6. A negative aspect of thrombolytic therapy is the 
possible occurrence of intracranial haemorrhage, 
What are the most important predictors of in tra­
cranial haemorrhage and excess of stroke with 
thrombolytic treatment?
7. Commonly used modes of reperfusion therapy in 
clinical practice include different thrombolytic 
regimens with streptokinase or (accelerated) tissue 
plasminogen activator, and direct angioplasty. 
What is the relationship between survival benefits, 
cerebral bleeding risks and costs for these three 
options?
8 . How can the benefits, risks and costs of different 
reperfusion strategies be integrated into clinical 
decision making?
A summary of the discussion of each of these 
issues is provided in the following sections, Although 
there was a consensus on most topics, in some areas 
agreement could not be reached and the alternative 
views are summarized. The occurrence of contrasting 
viewpoints can partly be explained by differences in 
emphasis on pathophysiological concepts and results 
of large trials. It should be appreciated, however, that 
these differences in interpretation do not lead to 
major differences in routine treatment strategies.
1. Reperfusion therapy preserves 
viable myocardial tissue and reduces 
mortality in acute myocardial infarction 
patients. Are left ventricular ejection 
fraction and infarct size adequate 
‘surrogate’ measures for the effects on
mortality and morbidity?
Infarct size can be measured from the total quantity 
of enzymes or other proteins released from the
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myocardium. Early reperfusion therapy results in 
rapid protein release[K2]. The total quantity of pro­
teins released (indicating infarct size) is reduced by 
20% to 35% with thrombolytic therapy compared 
with control11,3“51. Similarly, more effective reper­
fusion therapy yielded smaller infarct size than stan­
dard therapy[6,7J. In patients with a first infarct, 
infarct size is inversely correlated with residual left 
ventricular function^7,81. However, in most random­
ized controlled trials, differences in left ventricular 
ejection fraction between patients receiving reper­
fusion therapy and controls were small, although 
generally in favour of the treated group (pooled left 
ventricular ejection fraction 54% in treated patients 
vs 51% in controls)^91, whereas substantial survival 
benefits are demonstrated by large-scale randomized 
trials110,11]. In the Fibrinolytic Therapy Trialists9 
(FTT) collaborative overview of the nine largest 
comparisons of thrombolytic therapy vs control, this 
benefit was estimated to be 30 fewer deaths per 1000 
patients with ST elevation or bundle branch block 
treated within about 6 h from symptom onset[12l
Physiological studies might heighten our under­
standing of the possible mechanisms of action of 
thrombolytic treatment — for example, the relation­
ship between early coronary patency (TIMI-3 flow in 
the infarct related artery) and infarct size. Moreover, 
several studies have documented a close relationship 
between infarct size, residual left ventricular function, 
coronary patency and long-term survival^13,141. Al­
though studies measuring early coronary patency, 
enzymatic infarct size and ventricular function may 
give an indication of the effect of (new) reperfusion 
strategies, such studies cannot reliably determine the 
net clinical benefit of reperfusion therapy, Survival 
after myocardial infarction depends not only on early 
patency but also on sustained coronary patency and the 
healing process of the infarction. Furthermore, the risk 
of intracranial haemorrhage with treatment is largely 
independent of infarct size and left ventricular ejection 
fraction. Hence, determination of the balance between 
survival benefit and cerebral bleeding risk with differ­
ent treatment strategies requires large mortality trials.
Conclusions
* Coronary artery patency, left ventricular ejection 
fraction and infarct size (as determined by cumu­
lative myocardial protein release) can be used to 
make initial assumptions of the efficacy of reper­
fusion regimens.
•  Subsequently, large mortality trials are required to 
assess reliably the survival benefits and bleeding 
risks of reperfusion strategies.
2. Mortality with or without reperfusion 
therapy can be predicted by individual 
characteristics. What are the 
short-term effects of reperfusion 
therapy in different subgroups of 
patients?
Several studies have shown that the risk of death 
from acute myocardial infarction can be predicted at 
the time of hospital admission^15“211. Some determi­
nants of mortality cannot be altered by thrombolytic 
therapy, such as sex, age, baseline left ventricular 
function, a history o f infarction and location of the 
current infarct^181. The area of myocardium at risk 
can be estimated from total ST elevation on the 
presenting ECG and Killip class. Infarct size, as a 
proportion of the area at risk, can be influenced by 
reperfusion therapy, with greater salvage by earlier 
treatment. Thrombolytic therapy has been shown to 
improve survival in patients presenting with either ST 
elevation or bundle branch block within 12 h of 
symptom onset[12]. In  an overview of the large trials 
there was no significant heterogeneity between the 
proportional mortality reductions in the different 
subgroups of patients studied. Consequently, the 
absolute number of deaths avoided by thrombolytic 
treatment appears to be greater in those groups with 
a higher mortality risk. Moreover, there was no 
support for withholding thrombolytic therapy on the 
basis of age alone as the survival advantages were 
similar in young and old: 15 (SD4) lives saved per 
1000 treated aged <55 years, 21 (SD 5) aged 55-64, 
37 (SD 6) aged 65-74 and 13 (SD 14) aged >75 years, 
respectively. I t should be appreciated, however, that 
the estimate of benefit in patients aged 75 years or 
over is imprecise due to the relatively small number 
o f patients, and thus additional information from 
controlled trials would be valuable.
It is less clear whether there are worthwhile 
benefits among patients presenting with ST depres­
sion but without ST elevation or bundle branch 
block. Some of these patients have coronary occlu­
sion and evolving posterior infarction and are at high 
risk of death, and so may well benefit from th rom bo­
lytic therapy. Others may be suffering from unstable 
angina pectoris, with extensive ischaemia but w ithout 
occlusion of a major coronary artery, although a 
significant (non-occluding) stenosis may be present. 
In  these patients, coronary angiography and c o r­
onary angioplasty or bypass surgery are often 
indicated, but thrombolytic therapy is less likely to  
be useful. Further trials are warranted to identify 
patients with ST depression who do benefit from  
early reperfusion therapy.
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Another, not completely understood, phenom­
enon is the excess of deaths in thrombolytic treated 
patients on the first day, particularly in patients 
treated relatively late after onset of symptoms[12l  If 
there is a physiological reason for this early hazard 
which could be prevented then the benefits of throm­
bolytic therapy might be increased substantially.
Conclusions
•  Almost all patients with evolving myocardial in­
farction presenting with ST elevation or bundle 
branch block up to at least 12 h from symptom 
onset will benefit from thrombolytic therapy.
•  The proportional improvement in short-term sur­
vival produced by reperfusion therapy is generally 
similar in different subgroups of patients. Conse­
quently, in absolute terms, high-risk patients (e.g. 
older patients, those with a history of infarction, 
anterior location of the current infarct, extensive 
ST elevation or shock) may benefit most from such 
therapy.
•  More information is needed to define more accu­
rately the survival benefit in the very elderly (age 75 
years or over), and in patients with ST segment 
depression on the presenting ECG without ST 
segment elevation.
3. Improved survival with reperfusion 
therapy is sustained after the first year. 
What are the determinants of the 
long-term survival advantage after
reperfusion therapy?
Follow-up studies confirm that reperfusion therapy 
provides sustained survival benefit at 4, 5 and 10 
years114,18,23,241. In ISIS-2, streptokinase produced an 
absolute improvement in survival at 35 days of 29 
(SD 5) fewer deaths per 1000 treated patients, while 
the. absolute benefit was 28 (SD7) fewer deaths per 
1000 at 4 years. Hence, following the large divergence 
in survival during days 0-35, there was no significant 
divergence or convergence thereafter. The absolute 
benefit at 4 years among patients randomized within 
0-3 and 4-6 h of symptoms onset (48 [SD 13] and 18 
[SD 12], respectively) were similar to those at day 35 
(44 [SD 9] and 25 [SD 8]). The greater absolute ben­
efits observed at one month in patients at higher risk 
of death were also sustained; for example, among 
patients presenting with anterior ST elevation there 
were 71 (SD 11) and 62 (SD 15) fewer deaths per 1000 
at 35 days and 4 years, respectively. Other reports 
confirm these observations^4,18,243. By multivariate
analysis, long-term survival can be predicted from 
measurements at the time of hospital discharge in- 
chiding left ventricular function, enzymatic infarct 
size, number of diseased vessels, and TIM I perfusion 
grade1-13,14,24l  When such information is included, 
the initial therapy (thrombolysis or conventional) 
appeared not to be an independent predictor of 
long-term outcome. Thus the benefits of reperfusion 
therapy are obtained early after initiation of therapy, 
and are maintained thereafter.
One reservation expressed about the use of 
thrombolytic therapy in elderly patients is that any 
short-term  survival advantage might be only transi­
tory because of the high underlying mortality. How­
ever, although 4-year survival among patients aged 70 
years or over at entry into ISIS-2 was only about 
50%, the absolute reduction in 4-year mortality with 
streptokinase was at least as great among these 
patients (45 [SD 19] lives saved per 1000) as among 
those aged less than 70 years (23 [SD 7] lives saved 
per 1000). Thus, long-term benefits of reperfusion 
therapy are also apparent in elderly patients.
Conclusions
•  The absolute mortality reduction produced by 
reperfusion therapy is sustained after the first year, 
but there is no evidence that it increases with more 
prolonged follow-up.
•  Multivariate analysis of large trial databases 
may give more insight into the underlying relation­
ships between patient characteristics and the effects 
of thrombolytic therapy on early and long term 
survival.
4. The mortality reduction produced by 
reperfusion therapy is related to the 
time from symptom onset to treatment. 
What is the nature of this relationship?
Is there a first 'golden hour5 after 
symptom onset in which treatment 
benefits are particularly large?
All the participants agreed that the earlier reperfusion 
therapy is initiated, the larger the survival 
advantage[10_12,15,25]. There was disagreement, how­
ever, as to whether the benefits of treatment within 
the first hour after symptom onset are substantially 
greater (that is a 'golden hour5) than slightly later 
treatment^253, or whether there is only a gradual 
diminution of benefits with later treatment^121.
Eur Heart J, VoL 18, September 1997
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Figure 1 Absolute reduction in 35-day mortality vs treatment delay as reported by the FTT 
investigators112*. The loss of benefit per hour of delay to randomization was estimated at 1-6 
(SD 0*6) per 1000 patients. The black squares represent the average effects in five 
time-to~treatment groups. The areas of these squares are inversely proportional to the 
variance of absolute benefit it describes.
First viewpoint pre-hospital vs in-hospital fibrinolytic therapy could 
provide directly randomized evidence of the relevance
One view was that although earlier thrombolytic of an extra hour of delay, but even in aggregate they
treatment clearly produces greater benefit, the FTT are far too small to measure reliably differences of
overview of all relevant data from all nine trials that only a few deaths per 1000, and their combined
included more than 1000 patients (involving a total of results are consistent with their being little or no
46 000 randomized patients) indicated that the de- improvement in outcome with slightly earlier treat-
crease in the absolute benefit with increasing delay m e n t Moreover, with respect to assessing the effects
was fairly shallow, and was not significantly steeper 0f  very early treatment, the slight non-significant
in the first few hours than in subsequent hours (Fig. 
I)1121. A retrospective subgroup analysis of GISSI-1 
had suggested that fibrinolytic therapy might be 
especially effective when started within 1 h  from 
symptom onset, but this was not supported by the 
other large trials* Indeed, if GISSI-1 was excluded 
then the apparent benefit in those randomized in 
hours 0-1 was slightly below the sloping line in Fig. 1. 
Each hour of delay recorded among patients with ST 
elevation or bundle branch block was associated with 
a reduction in benefit of about 1*6 (SD 0*6) deaths per
benefit of about 1 h earlier treatment in the largest 
trial (EMIP) was observed in those randomized 3-6 h 
after symptom onset, and not in those entered within
3 h ^ .
Second viewpoint
In contrast to this first view, it was pointed out that 
an occlusion of less than 30 min in animals generally 
does not lead to irreversible myocardial damage[27-29],
1000 patients. This estimate may have been somewhat and small observational studies in humans support 
diluted by inaccuracies in assessing the delays, and so the plausibility of similar patterns[30,311. Studies com-
the real effect of each additional hour of delay may 
well be slightly greater, involving perhaps two (or
pairing pre-hospital and in-hospital therapy suggest 
a  greater effect with earlier treatment^26*32,333. For 
even three) extra deaths per 1000, per hour. (The example, the largest study (EMIP) reported 15 fewer
results of an analysis that included all smaller trials, 
i.e. at least 100 patients1353, may be biased because 
results for patients randomized within 0-1 h of symp­
tom onset were not listed separately for several of 
these smaller trials, and those smaller trials that did
deaths per 1000 treated at a median of 2*2 h instead of 
3’2 h  after onset of symptoms (95% confidence limits: 
27 fewer deaths to 1 additional death per 1000 
treated, ns), albeit that most of this benefit was 
realised in patients treated between 3 and 6 h after
report such information may have done so because onset of symptomst26]. Although the pre-hospital 
their results were extreme.) In principle, the trials of trials were relatively small and the individual results
Eur Heart J, Vol. 18, September 1997
Clinical Perspectives 1375
80
m
ti
CD
•  r H
CO&
cd4-3
ctf
CD
jj
ooorH
in
CDa
«0A<D
d 
r — Hom
<i
60
40
20 -
0
Treatment delay (h)
Figure 2 Absolute 35-day mortality reduction vs treatment delay as reported by a 
re-analysis of the FTT data in combination with data from smaller trials (at least 100 
patients) that randomized between fibrinolytic therapy and control or placebo1351« The small 
closed dots represent information from trials included in the FTT analysis, the open dots 
represent information from additional trials. The small squares mark data beyond the scale 
of the y-axis. Linear (34*7-l*6x) and non-linear (19*4~0'6x+29’3x “ *) regression lines are 
fitted within these data. The best fit was obtained with the non-linear mathematical function 
(significant contribution of the x ~ ‘-component; largest Revalue). The black squares 
represent the average effects in six time-to-treatment groups. The areas of these squares are 
inversely proportional to the variance of absolute benefit it describes.
were not statistically significant, significance was 
reached in pooled analyses of the data[25,34].
The concept of a first ‘golden hour’ is sup­
ported by a re-analysis of the large trials in the FTT 
report in combination with data from smaller trials 
(at least 100 patients) that randomized patients be­
tween fibrinolytic therapy and control1351. This analy­
sis showed that the delay/benefit relationship could be 
significantly better described with a non-linear than 
with a linear function (see Fig. 2) The decrease in 
benefit up to approximately 1*5 h from symptom 
onset was about 30 lives per 1000 treated per hour, 
and declined rapidly to approximately three lives per 
hour in the 1 *5-4*0 h interval and only 1*4 lives per 
hour after this period. Thus an extra effort to treat 
earlier (e.g. pre-hospital identification and therapy, 
and optimization of in-hospital logistics) will be par­
ticularly effective for patients reporting within the 
first hours after symptom onset, while some ad­
ditional delay is less harmful in patients presenting 
late.
Conclusions
•  It is clear that the earlier reperfusion therapy is 
started after the onset of symptoms, the larger the 
mortality reduction.
•  There is no agreement as to the shape of the 
association between the mortality benefit and time 
from symptom onset to treatm ent for patients 
treated within the first few hours, and of the 
existence of a first 'golden hour’.
5. Do patients treated late after onset 
of symptoms — between 12 and 
24 h — also benefit from reperfusion 
therapy?
Approximately 30% of patients with acute myocar­
dial infarction arrive in hospital beyond the currently 
accepted time limit for reperfusion therapy, that is, 
more than  12 h from symptom onset[36]. Pharm aco­
logical or mechanical achievement of patency is poss­
ible in these late arrivals^373, and vessel patency may 
help to preserve left ventricular function or improve 
infarct healing and recovery, although significant 
myocardial salvage will probably not occur[38l
Overall, 7000 patients with ST elevation or 
bundle branch block presenting between 12 and 24 h 
from symptom onset have been randomized between 
fibrinolytic therapy and control111*22,36,391. Although 
the absolute benefit o f seven (SD 7) fewer deaths per 
1000 treated observed among these patients was
Enr Heart J, Vol. 18, September 1997
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non-significant[12], benefit with earlier treatment and 
the gradual diminution of benefit with later treatment 
(see Figs 1 and 2) does suggest that worthwhile net 
benefits may await discovery among patients who 
present within 12 to 18 h or so after onset, especially 
if there are signs of ongoing ischaemia.
This suggestion is supported by subgroup ob­
servations in the LATE trial. Patients presenting after 
12 h who were treated soon after admission, generally 
because of clear evidence of ischaemia, showed a 22% 
relative mortality reduction with tissue plasminogen 
activator1361. In contrast, among those patients in 
whom the decision for therapy was delayed until an 
observational period o f 3 h or longer, no beneficial 
effect was observed. Thus, patients presenting more 
than 12 h from symptom onset with clear indications 
of immediate thrombolytic therapy, i.e. ongoing chest 
pain or other signs of ongoing ischaemia (ECG), 
may benefit. Perhaps this is because some of these 
patients do not have continuous coronary occlusion, 
but rather intermittent occlusions —  a ‘stuttering 
infarction’ — so that partial salvage of ischaemic 
myocardium may be achieved in them140,413,
Conclusions
•  Reperfusion therapy may be justified in patients 
with signs of ongoing ischaemia presenting between 
12 and 24 h after symptom onset,
•  Further study of the effect of reperfusion therapy in 
patients presenting late, and the mechanism of such 
effect, is needed.
6. A negative aspect of thrombolytic 
therapy is the possible occurrence of 
intracranial haemorrhage« What are 
the most important predictors of 
intracranial haemorrhage and excess 
stroke with thrombolytic treatment?
Intracranial haemorrhage is a rare event in patients 
with myocardial infarction receiving conventional 
therapy. Thrombolytic therapy does increase the rate 
of intracranial haemorrhage, despite attempts to avoid 
treating patients with an increased bleeding risk (par­
ticularly those with a recent cerebrovascular accident 
or with a cranial trauma). On the other hand, em­
bolic stroke rates may be slightly reduced in patients 
receiving thrombolytic therapy, perhaps because of 
infarct size reduction and the anticoagulant effects of 
thrombolytic agents. Overall, the excess of any stroke 
(haemorrhagic or embolic) with thrombolytic therapy
appears to be small, averaging about four (SD 0-8) per 
1000 patients treated in the large studies112J. About 
half of these strokes were fa ta l  O f the survivors about 
half were moderately or severely disabled while the 
others experienced little or no disability^431.
A few independent predictors for intracranial 
haemorrhage were identified by a case control study 
which included 150 patients with such bleeding and 
294 matched controls from various trials. These 
predictors were age over 65 years, body weight 
below 70 kg, hypertension (defined as blood pres­
sure greater than 165/95 m m Hg) on hospital admis­
sion and the use of alteplase (vs streptokinase)^421. 
These findings were supported by analyses of the 
GUSTO-1 database, which found age (median age 
of patients without and with haemorrhagic stroke 
was 61 and 70 years, respectively) and previous 
cerebrovascular disease to be risk factors for intra­
cranial bleeding (although the latter was an exclu­
sion criterion in the trial)[43l
Even though it is possible to identify sub­
groups of patients with increased intracranial bleed­
ing risk from observational data, the large 
randomized trials did not demonstrate a significant 
excess risk due to thrombolytic therapy in these 
subgroups*121. In the FTT analysis, an excess of 
strokes with thrombolytic therapy occurred during 
day 0- 1, and was mainly due to an increase in 
intracranial haemorrhage. This early excess appeared 
to be somewhat greater in patients aged 75 years and 
above, but it was not significantly greater than in 
those aged 55-74 years (and strokes were rare among 
those under 55 years). The excess of all strokes 
(haemorrhagic and embolic) during the hospital stay 
was also not strongly related to age, blood pressure or 
other patient characteristics.
The available evidence, therefore, supports the 
use of thrombolytic therapy in most patients present­
ing with ST segment elevation or bundle branch block 
within 12 h of symptom onset unless a markedly 
increased bleeding risk can be identified. In each 
individual patient the likely benefits and risks of 
thrombolytic therapy should be weighed carefully. 
But risks should not be exaggerated as this may result 
in inappropriate under-treatment.
Conclusions
•  Thrombolytic therapy carries an increased risk for 
intracranial haemorrhage, while embolic strokes 
are slightly reduced. Overall, thrombolytic treat­
ment is associated with about four extra strokes per 
1000 patients treated. However, in all categories of 
patients presenting with ST segment elevation or
Eur Heart J, Vol. 18, September 1997
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bundle branch block within 12 h that have been 
studied, the survival benefits of thrombolytic 
therapy outweigh the risks.
•  Advanced age, a history of cerebrovascular disease, 
low body weight, hypertension on hospital admis­
sion as well as a recent head trauma are important 
risk factors for the occurrence of intracranial bleed­
ing complications. However, the excess risk of early 
strokes (mainly intracranial haemorrhage) or of 
total strokes due to thrombolysis are not strongly 
related to age, blood pressure or other patient 
characteristics.
7- Commonly used modes of 
reperfusion therapy in clinical practice 
include different thrombolytic regimens 
with streptokinase or (accelerated) 
tissue plasminogen activator, and 
direct angioplasty. What is the 
relationship between survival benefits, 
cerebral bleeding risks and costs for 
these three options? Comparisons of 
different thrombolytic regimens
Different thrombolytic regimens, whether based on 
streptokinase, (accelerated) recombinant tissue plas­
minogen activator or anisoylated plasminogen 
streptokinase activator complex (APSAC), have all 
been shown to produce substantial improvements in 
survival. There was no agreement, however, as to 
whether there was any worthwhile net difference in 
clinical outcome between the different thrombolytic 
regimens that have been studied.
First viewpoint
Neither the GISSI-2/International trial nor ISIS-3 
found a survival difference between streptokinase 
(1 '5M U  infused over 1 h, either with or without 
subcutaneous heparin) or tissue plasminogen acti­
vator (alteplase/duteplase infused over 3 to 4 h, also 
with or without heparin)[39,44v45l  The G U STO -1 in­
vestigators, however, reported a significant reduction 
in 30-day mortality of 10 (SD 3) per 1000 patients 
treated with accelerated administered tissue plasmino­
gen activator (alteplase infused over 1*5 h, combined 
with intravenous heparin) compared with the stan­
dard streptokinase regimen (either with subcutaneous 
or intravenous heparin)1-461. This benefit was main­
tained for at least 1 year[47l, and was observed in 
almost all subgroups, including elderly patients, and 
those presenting after 3 h. Some questions have been
raised about supposed differences in outcome be­
tween U.S. and non-U,S. patients, but these non­
significant differences could largely be explained by 
differences in baseline characteristics between patients 
enrolled in these two continents[48l
The risk of non-fatal stroke (especially of 
intracranial haemorrhage) is increased with tissue 
plasminogen activator compared with streptokinase. 
In GUSTO-1, a significant absolute increase in total 
stroke was reported of 2’6 (SD 1*5) per 1000 patients 
treated with accelerated tissue plasminogen activator. 
Nevertheless, the absolute net clinical benefit, of the 
combined end point of 30-day mortality or non-fatal 
stroke was still nine (SD 3) patients per 1000 treated 
with accelerated tissue plasminogen activator. Thus, 
accelerated  tissue plasminogen activator has been 
shown to be clearly superior to streptokinase.
In spite of the favourable outcome with accel­
erated tissue plasminogen activator, application in 
clinical practice remains limited by the relative high 
costs. A cost-effectiveness study of the GUSTO data 
estimated the additional costs of accelerated tissue 
plasminogen activator compared with streptokinase 
at $27 369 per life year added, based on the cost of 
tissue plasminogen activator in the 'U.S.t491. Accord­
ingly, accelerated tissue plasminogen activator was 
recommended in patients who might benefit greatly 
from reperfusion therapy, i.e. those with a high 
mortality risk without thrombolysis1181.
Second viewpoint
In contrast with this first view, it was argued that, 
when the totality of the clinical trial evidence is 
considered, there is no good evidence that any par­
ticular thrombolytic regimen is clearly better. More 
intensive regimens, generally based on tissue plas­
minogen activator, do not increase the overall p ro ­
portion of arteries eventually opened within the first 
few hours, but they did work slightly more rapidly. 
Although opening the arteries half an hour or one 
hour earlier should produce some cardiac benefit, the 
fundamental question is whether any cardiovascular 
advantages from more intensive thrombolytic regi­
mens outweigh any cerebrovascular disadvantages.
In the three large trials of the standard 1 h 
1*5 M U  streptokinase regimen vs tissue plasminogen 
activator-based fibrinolytic regimens, patients were 
entered on average about 2-3 li after the onset of 
symptoms in GISSI-2, 4 h  in ISIS-3 and 2 h  in 
G U S T O -l[39,44i46^ . In each, the tissue plasminogen 
activator-based regimens were designed to ensure 
appreciably better 90-min coronary artery patency 
than the standard streptokinase regimen with which
Eur Heart J, Vol. 18, September 1997
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they were compared, and the accompanying dose of 
aspirin was sufficiently large to contribute substan­
tially towards the maintenance of that early patency. 
Moreover, both of the tissue plasminogen activator- 
based regimens in GUSTO-1 were very similar to 
each other in terms of the total dose given in the first 
hour (82 mg of alteplase with the accelerated tissue 
plasminogen activator-alone regimen and 78 mg of 
alteplase with the other tissue plasminogen activator- 
based regimen) and in terms of 90-min TIMI 2/3 
patency. Hence, it is most appropriate — in order 
to avoid selective emphasis on particular trial 
results — to consider all three trials to g e th e r^ .
Overall in these trials, there was a highly 
significant excess of 3*3 (SDO-8) strokes per 1000 
treated with tissue plasminogen activator compared 
with streptokinase1501, Most of this excess occurred 
within the first day of giving tissue plasminogen 
activator, and was attributed to an even more definite 
excess of 2*9 (SD 0-5) cerebral haemorrhages per 
1000. These excesses with the tissue plasminogen 
activator regimens increased with increasing age and 
blood pressure. Overall, the tissue plasminogen 
activator-based regimens were associated with 4-9 
(SD 1*8) fewer non-stroke deaths per 1000 compared 
with streptokinase, but the 95% confidence interval 
for this estimate spans a wide range from about one 
to about nine fewer non-stroke deaths per 1000, 
When taken all together, the directly randomized 
comparisons suggest such tissue plasminogen 
activator-based regimens might confer a non­
significant improvement of only one or two per 1000 
in net clinical outcome. But, whereas the hazard is 
definite (about three additional cerebral haemor­
rhages per 1000) any excess of benefit over hazard is 
uncertain.
Comparison o f  thrombolytic therapy versus 
primary angioplasty
Preliminary results from a pooled analysis of data 
from three small trials of thrombolytic therapy (405 
patients; 256 tissue plasminogen activator and 149 
streptokinase) vs angioplasty (394 patients) indicated 
a favourable outcome with the latter strategy (6*4% 
vs 2* 6% in-hospital mortality; reduction of 39 per 
1000, with a 95% confidence interval of 10 to 68, 
P=0-01)[7,51~541. This apparent mortality advantage 
of primary angioplasty was observed largely among 
patients at somewhat higher risk (elderly, anterior 
infarction, increased heart rate) and appeared to be 
associated with fewer strokes, although these appar­
ent benefits are uncertain due to the small numbers 
of patients studied in these trials. In the recently
completed larger (n=1138) GUSTO-2b substudy of 
accelerated tissue plasminogen activator vs direct 
angioplasty, however, the observed differences in 
survival were less striking: 30-day mortality was 5*7% 
in the direct percutaneous transluminal coronary 
angioplasty group vs 7*0%) in thrombolytic-treated 
patients (a non-significant difference with a 95%o 
confidence interval of 15 more to 40 fewer deaths per 
1000 angioplasties). The combined 30-day endpoint 
o f death, re-infarction or disabling stroke was signifi­
cantly lower in patients treated with direct percu­
taneous transluminal coronary angioplasty (9*6%) 
compared with thrombolytic therapy (13*7%); reduc­
tion of 41 per 1000, but with 95%) confidence interval 
o f 3 to 78, P=0*033)[55].
The initial costs of an angioplasty procedure 
are relatively high. However, some of these costs may 
be offset during follow-up. Costs after thrombolytic 
therapy may be higher, due to a higher number of 
interventions and re-admissions[56].
Conclusions
•  Any differences in outcome between reperfusion 
strategies are likely to be small in comparison with 
the differences in outcome between reperfusion 
therapy and no reperfusion therapy. Hence, most 
emphasis should be on ensuring that eligible 
patients receive some effective reperfusion therapy 
as rapidly as is practicable without worrying over­
much about which strategy to choose.
•  Tissue plasminogen activator-based therapy pro­
duces a higher rate of early coronary patency and, 
probably, some improvement in cardiac mortality. 
O n the other hand, treatment with tissue plasmino­
gen activator is associated with a greater risk of 
early intracranial haemorrhage compared with the 
‘standard’ streptokinase regimen. The balance of 
advantages (survival) and disadvantages (cerebral 
bleeding) with tissue plasminogen activator is 
judged differently. Some investigators are con­
vinced that the use of accelerated alteplase with 
intravenous heparin yields a significant net clinical 
benefit over streptokinase, while others consider 
th a t whereas the hazard with tissue plasminogen 
activator is definite any excess of benefit over 
hazard  is uncertain.
•  Direct angioplasty may be more effective at reduc­
ing mortality than thrombolytic therapy, although 
the current estimates of benefit are uncertain due to 
the relatively small number of randomized patients 
studied. Primary angioplasty may be offered as an 
alternative to thrombolytic therapy in centres with
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adequate facilities and experience, particularly in 
patients with large infarcts and increased cerebral 
bleeding risk.
•  Additional much larger studies are needed to com­
pare the (cost)-efficacy of direct angioplasty and 
thrombolytic therapy reliably.
8. How can the benefits, risks and 
costs of different reperfusion 
strategies be integrated into clinical 
decision making?
In clinical practice a physician must choose for each 
individual patient between different therapies with 
different costs and efficacy. This choice is often re­
stricted by limited resources or organizational con­
straints (e.g. availability of direct angioplasty). Since 
the effect of reperfusion therapy is strongly related to 
treatment delay, in the acute setting there is little time 
in which to weigh up the potential benefits and risks 
of different treatment regimens in an individual 
patient. In this situation, a treatment protocol may be 
a powerful tool to help rapid decision-making in a 
consistent manner, although this cannot replace the 
physician’s clinical impression of the patient.
A range of treatment guidelines for individual 
patients has been developed. Ideally such protocols 
would first provide reliable estimates of the expected 
treatment benefit, for example the gain in one year 
survival, based on a limited number of relevant 
individual characteristics (such as the duration of 
symptoms, age and ECG changes). Secondly, a 
reliable estimate of the patient’s (cerebral bleeding) 
risk from treatment would be estimated. Finally, 
benefits and risks would be weighed, and advice given 
on whether or not to use reperfusion therapy and 
possibly on the choice of therapy. Such reperfusion 
treatment protocols might be presented on simple 
paper charts, or might involve the assistance of a 
computer program[18,20,57~62l
Conclusions
•  A reliable reperfusion treatment protocol may be a 
powerful tool to assist in the optimal and consistent 
treatment of acute myocardial infarction patients.
•  Protocols need to be evaluated, improved and 
extended. Analysis of large databases from clinical 
trials, as well as from prospective studies and 
registries in clinical practice, would help in this 
task.
Future directions
The introduction of reperfusion therapy has consid­
erably improved the prognosis of patients with evolv­
ing myocardial infarction during the last decade. 
Mortality at 1 m onth has been reduced by approxi­
mately 30 deaths per 1000 patients treated within 
6 h from symptom onset, despite a small excess of 
cerebral bleeding complications (approximately four 
per 1000).
Analysis of existing trial data has shown that 
the absolute benefit o f reperfusion therapy is largely 
dependent on the patient’s baseline mortality risk and 
the time elapsed from onset of symptoms. Therefore, 
future investigations should concentrate on:
•  early initiation of thrombolytic therapy and further 
evaluation o f the effectiveness and costs of pre­
hospital thrombolytic treatment;
•  evaluation of the effects of thrombolytic therapy in 
those patient subgroups for which uncertainty 
about clinical benefit exists (e.g. those presenting 
after 12 h from symptom onset and those without 
ST elevation or bundle branch block);
•  development of better thrombolytic regimes, that 
produce coronary patency rapidly without in­
creasing the risk of cerebral haemorrhage (e.g. 
combination o f thrombolytic drugs and powerful 
anti-thrombotic agents, such as the GP Ilb/IIa 
receptor blockers);
•  evaluation of the effects of newer antithrombotics 
on sustained patency;
•  study o f the mechanisms of the early mortality 
associated with thrombolytic therapy and of ways 
to avoid it;
•  further analysis o f primary percutaneous trans­
luminal coronary angioplasty (perhaps in combi­
nation with coronary stenting) as an alternative for 
thrombolytic therapy.
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